<DOC>
	<DOCNO>NCT01303380</DOCNO>
	<brief_summary>This pilot study design evaluate efficacy , safety , pharmacokinetics ( PK ) / pharmacodynamics ( PD ) canakinumab treatment patient HIDS .</brief_summary>
	<brief_title>Canakinumab Patients With Active Hyper-IgD Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Mevalonate Kinase Deficiency</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients diagnosis HIDS proven DNA analysis and/or enzymatic study . 2 . At time start drug treatment : active HIDS evidence physician global assessment HIDS flare severity â‰¥ 2 CRP value &gt; 10 mg/L ( normal CRP &lt; = 10 mg/L ) . 3 . Patients history &gt; = 3 febrile acute HIDS flare 6month period receive prophylaxis treatment ( e.g . anakinra daily treatment ) duration flare last &gt; = 4 day limit normal daily activity . 1 . Pregnant nursing ( lactate ) woman . 2 . History immunocompromised , include positive HIV screening ( ELISA Western blot ) test result . 3 . Positive Hepatitis B Hepatitis C. 4 . Live vaccination within 3 month prior start trial 5 . Positive tuberculosis screen test . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hyper IgD syndrome</keyword>
	<keyword>canakinumab</keyword>
	<keyword>HIDS</keyword>
	<keyword>mevalonate kinase deficiency</keyword>
	<keyword>MKD</keyword>
</DOC>